Amy Heaps
University of Pittsburgh
18 Papers
28 Citations
Amy Heaps is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Medicine & Immunology. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study.
Matthew K Hensley,William Bain,William Bain,Jana L. Jacobs,Sham Nambulli,Urvi M. Parikh,Anthony R. Cillo,Brittany Staines,Amy Heaps,Michele D. Sobolewski,Linda J. Rennick,Bernard J.C. Macatangay,Cynthia Klamar-Blain,Georgios D Kitsios,Barbara Methé,Ashwin Somasundaram,Tullia C. Bruno,Carly Cardello,Feng Shan,Creg J. Workman,Prabir Ray,Anuradha Ray,Janet S. Lee,Rahil Sethi,William E. Schwarzmann,Mark S. Ladinsky,Pamela J. Bjorkman,Dario A. A. Vignali,W. Paul Duprex,Mounzer Agha,John W. Mellors,Kevin D. McCormick,Alison Morris,Ghady Haidar +33 more
TL;DR: In this article, a chimeric antigen receptor-modified T-cell therapy recipient developed severe coronavirus disease 2019, intractable RNAemia, and viral replication lasting >2 months.
Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study.
Ghady Haidar,Mounzer E. Agha,Andrew Bilderback,Amy Lukanski,Kelsey Linstrum,R. Troyan,Scott D. Rothenberger,Deborah McMahon,Melissa D Crandall,M. Sobolewksi,P. Nathan Enick,Jana L. Jacobs,Kevin Collins,Cynthia Klamar-Blain,Bernard J.C. Macatangay,Urvi M. Parikh,Amy Heaps,Lindsay Coughenour,Marc Schwartz,Jeff Dueker,Fernanda P. Silveira,Mary E. Keebler,Abhinav Humar,James D. Luketich,Matthew R. Morrell,Joseph M. Pilewski,John F. McDyer,Bhanu P. Pappu,Robert L. Ferris,Stanley M. Marks,J.R. Mahon,Katie Mulvey,Sundaram Hariharan,Glenn Updike,Lorraine Brock,R.E. Edwards,Richard H. Beigi,P. L. Kip,Alan Wells,Tami Minnier,Derek C. Angus,John W. Mellors +41 more
TL;DR: Antibody responses to COVID-19 vaccines were lowest among SOT and anti-CD20 monoclonal recipients, and recipients of vaccines other than mRNA-1273, and among those with intermediate antibody levels, pseudovirus neutralization titers were lower in immunocompromised patients than HCW.
51
Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS)
Ghady Haidar,Mounzer E. Agha,Andrew Bilderback,Amy Lukanski,Kelsey Linstrum,R. Troyan,Scott D. Rothenberger,Deborah McMahon,Melissa D Crandall,M. Sobolewksi,P. Nathan Enick,Jana L. Jacobs,Kevin Collins,Cynthia Klamar-Blain,Bernard J.C. Macatangay,Urvi M. Parikh,Amy Heaps,Lindsay Coughenour,Marc B Schwartz,Jeff Dueker,Fernanda P. Silveira,Mary E. Keebler,Abhinav Humar,James D. Luketich,Matthew R. Morrell,Joseph M. Pilewski,John F. McDyer,Bhanu P. Pappu,Robert L. Ferris,Stanley M. Marks,J.R. Mahon,Katie Mulvey,Sundaram Hariharan,Glenn Updike,Lorraine Brock,R.E. Edwards,Richard H. Beigi,P. L. Kip,Alan Wells,Tami Minnier,Derek C. Angus,John W. Mellors +41 more
TL;DR: Antibody responses to COVID-19 vaccines were lowest among SOT and anti-CD20 monoclonal recipients, and recipients of vaccines other than mRNA-1273, and among those with intermediate antibody levels, pseudovirus neutralization titers were lower in immunocompromised patients than HCWs.
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients: An Observational, Prospective Cohort Study Interim Analysis
Ghady Haidar,Mounzer Agha,Amy Lukanski,Kelsey Linstrum,Rachel Troyan,Andrew Bilderback,Scott D. Rothenberger,Deborah McMahon,Melissa Crandall,P. Nathan Enick,Michelle Sobolewksi,Kevin Collins,Marc Schwartz,Jeffrey Dueker,Fernanda P. Silveira,Mary E. Keebler,Abhinav Humar,James D. Luketich,Matthew R. Morrell,Joseph M. Pilewski,John F. McDyer,Bhanu Pappu,Robert L. Ferris,Stanley M. Marks,Cynthia Klamar-Blain,Urvi M. Parikh,Amy Heaps,Paula L Kip,Alan Wells,Tami Minnier,Derek C. Angus,John W. Mellors +31 more
TL;DR: In this article, an interim analysis of an ongoing observational, prospective cohort study which launched on April 14, 2021 across Western Pennsylvania was conducted to measure antibody responses, levels, and neutralization capability after COVID-19 vaccination among immunocompromised patients.
Therapy with Allogeneic SARS-CoV-2-specific T-cells for Persistent COVID-19 in Immunocompromised Patients.
Ghady Haidar,Jana L. Jacobs,K. Hughes Kramer,Asma Naqvi,Amy Heaps,Urvi M. Parikh,Kevin McCormick,Michele D. Sobolewski,Mounzer E. Agha,Tatiana Bogdanovich,Vasilii Bushunow,Rafic Farah,Matthew K. Hensley,Y.-S. Hsu,Cynthia Klamar-Blain,Jennifer M Kozar,Elizabeth A. Lendermon,Bernard J.C. Macatangay,Anastasios Raptis,Fernanda P. Silveira,Ann M. Leen,William L. Marshall,Badrish Patel,Ercem S. Atillasoy,John W. Mellors +24 more
TL;DR: In this paper , SARS-CoV-2 VST was administered to 6 immunocompromised patients with persistent COVID-19 and characterized clinical and virologic responses: three patients had partial responses after failing other therapies but then died.